Queen’s Award and Expansion Underpin Next Growth Phase

Clintec, a global full service CRO, was presented with the Queens Award for Enterprise 2017, in the category of International Trade, by Lord Provost, Eva Bolander in her capacity as Lord Lieutenant. The award ceremony coincided with the official opening of an additional 4327sq feet floor at the company’s Glasgow-based headquarters, forming a centre of excellence for clinical research and quality assurance capabilities.

Company founder and CEO, Dr Rabinder Buttar said: “We are honoured to have received the Queens Award for Enterprise for the second time – through which we celebrate 20 years of global success in clinical research. Furthermore, we are delighted to mark today with the expansion of our clinical operational capabilities and HQ office space for the next stage of company growth.”

She added: “Clintec’s high quality performance and service offering that we have consistently delivered to our customers over the past two decades, is well acknowledged. This includes our global footprint, with local expertise, flexibility, agility and high level of service with senior management closely involved in the innovative clinical development programmes we expertly deliver.”

Lord Provost Eva Bolander said: “Clintec International Ltd is a phenomenal success story. It therefore gave me immense pleasure, as Lord Lieutenant, to present its founder and Chief Executive, Dr Rabinder Buttar, with the Queen’s Award for International Trade. This dynamic Glasgow based company, which I was delighted to be given a tour of, has excelled itself in its short lifetime contributing to the city’s diverse business life. This represents its second Queen’s Award. It already has a highly deserved Queen’s Award for Enterprise.”

During the same day, Sophie Totten, the company’s first Master’s Graduate in International Clinical Research & Technology, was recognised for her achievement obtaining her Master’s Degree, which has been developed jointly by Clintec and Edinburgh Napier University.